SIMULATIONS PLUS INC

Company Overview

Simulations Plus Inc. is a Healthcare sector company in the Health Information Services industry that develops biopharma software and provides scientific consulting to accelerate drug discovery, development, clinical trials, regulatory submissions, and commercialization. Its business is centered on model-informed drug development and quantitative systems pharmacology/toxicology tools, with software products such as ADMET Predictor, GastroPlus, DILIsym, Thales, MonolixSuite, Pro-ficiency, and Panorama KOL Insights. The company serves pharmaceutical and biotechnology customers worldwide, along with agrochemical, cosmetics, food, academic, and government/regulatory users. It has a science-heavy, globally marketed model with a remote-first operating footprint and a strong emphasis on AI, cloud, and validated scientific workflows.

Executive Compensation Practices

Executive compensation at Simulations Plus is likely influenced by both recurring software subscriptions and consulting utilization, as well as longer-cycle enterprise adoption in pharma and biotech. Given the company’s recent revenue growth, margin recovery, and renewed investment in R&D, incentive plans may emphasize top-line growth, gross margin, operating cash flow, and product development milestones rather than just EPS, especially after the large fiscal 2025 impairment-driven loss. In this sector, executives are often rewarded for retention of key scientific talent, expansion of recurring software revenue, successful integration of acquisitions, and progress in AI-enabled product commercialization. Stock-based compensation is also likely to be an important pay element, but valuation volatility from impairment charges and acquisition-related integration risk can make performance-based equity design particularly relevant.

Insider Trading Considerations

Insider trading patterns in the Health Information Services industry often reflect management’s view on customer demand, renewal cycles, and the pace of scientific product adoption, which can be lumpy in a niche, conference-driven sales model like Simulations Plus. Because the company’s results are seasonal and management has highlighted product mix, utilization, and R&D investment as key drivers, insiders may trade around visibility into software bookings, services utilization, and acquisition-related performance. The company’s exposure to impairment testing, capitalized software development, and strategic acquisition activity may also make insiders especially sensitive to valuation changes and integration outcomes. Trading activity may additionally be shaped by confidentiality constraints around pharma customer relationships, regulatory expectations, and the company’s global IP-heavy software portfolio.